4//SEC Filing
Vanda Pharmaceuticals Inc. 4
Accession 0001209191-13-038505
$VNDACIK 0001347178operating
Filed
Jul 30, 8:00 PM ET
Accepted
Jul 31, 4:34 PM ET
Size
7.6 KB
Accession
0001209191-13-038505
Insider Transaction Report
Form 4
Repella Robert
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2013-07-29+9,375→ 24,375 total - Exercise/Conversion
Restricted Stock Unit
2013-07-29−9,375→ 9,375 total→ Common Stock (9,375 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.
- [F2]As reflected in Table I of this Form 4, 50% of the original RSU award vested on July 29, 2013 upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder. The remaining unvested portion of the RSU award shall vest in four equal annual installments beginning January 1, 2014, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F3]Not Applicable.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001347178
Filing Metadata
- Form type
- 4
- Filed
- Jul 30, 8:00 PM ET
- Accepted
- Jul 31, 4:34 PM ET
- Size
- 7.6 KB